Atherosclerosis-targeted liposome nanocarrier delivery system and preparation method therefor
US-2024424132-A1 · Dec 26, 2024 · US
Methods of treating α adrenergic mediated conditions
US9623006B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9623006-B2 |
| Application number | US-201514692042-A |
| Country | US |
| Kind code | B2 |
| Filing date | Apr 21, 2015 |
| Priority date | Jun 9, 2008 |
| Publication date | Apr 18, 2017 |
| Grant date | Apr 18, 2017 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
Described herein are compounds for and methods of treating conditions or diseases in a subject by administering to the subject a pharmaceutical composition containing an effective amount of an α-adrenergic modulator. The compounds and methods are also useful for alleviating types of pain, acute, neuropathic and chronic.
First claim
Opening claim text (preview).
What is claimed is: 1. A method of treating a disease or condition in a mammal, the method comprising administering to the mammal in need thereof a pharmaceutically effective dose of N-(2,3-dichlorobenzyl)-4,5-dihydro-1H-imidazol-2-amine having the following structure: or a pharmaceutically acceptable salt thereof; wherein the disease or condition is selected from the group consisting of optic neuropathy, corneal pain and diabetic retinopathy. 2. The method according to claim 1 , wherein the disease or condition is corneal pain. 3. The method according to claim 1 , wherein the disease or condition is optic neuropathy. 4. The method according to claim 1 , wherein the disease or condition is diabetic retinopathy. 5. The method according to claim 1 , wherein the mammal is a human.
Assignees
Inventors
Classifications
Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] · CPC title
Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole · CPC title
having a nitrogen attached in position 2, e.g. clonidine · CPC title
with carbocyclic radicals directly attached to said nitrogen atoms · CPC title
- A61K31/40Primary
having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US9623006B2 cover?
- Described herein are compounds for and methods of treating conditions or diseases in a subject by administering to the subject a pharmaceutical composition containing an effective amount of an α-adrenergic modulator. The compounds and methods are also useful for alleviating types of pain, acute, neuropathic and chronic.
- Who is the assignee on this patent?
- Allergan Inc
- What technology area does this patent fall under?
- Primary CPC classification A61K31/40. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Apr 18 2017 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).